Robert A Soslow

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5874379/publications.pdf

Version: 2024-02-01

358 papers	26,396 citations	3334 91 h-index	9861 141 g-index
365 all docs	365 docs citations	365 times ranked	17844 citing authors

#	Article	IF	Citations
1	COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 2000, 89, 2637-2645.	4.1	798
2	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	1.6	613
3	Classification of endometrial carcinoma: more than two types. Lancet Oncology, The, 2014, 15, e268-e278.	10.7	479
4	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 2013, 123, 517-25.	8.2	462
5	TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic highâ€grade serous carcinomaâ€"evidence supporting the clonal relationship of the two lesions. Journal of Pathology, 2012, 226, 421-426.	4.5	332
6	Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell, 2002, 1, 53-62.	16.8	330
7	Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma. American Journal of Surgical Pathology, 2013, 37, 874-881.	3.7	309
8	Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell, 2017, 31, 411-423.	16.8	309
9	Antibody to transforming growth factor-Î² ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney International, 2000, 58, 2301-2313.	5.2	303
10	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nature Genetics, 2014, 46, 424-426.	21.4	291
11	Pathologic Classification and Clinical Behavior of the Spectrum of Goblet Cell Carcinoid Tumors of the Appendix. American Journal of Surgical Pathology, 2008, 32, 1429-1443.	3.7	284
12	Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas. American Journal of Surgical Pathology, 2008, 32, 1566-1571.	3.7	263
13	International Endocervical Adenocarcinoma Criteria and Classification (IECC). American Journal of Surgical Pathology, 2018, 42, 214-226.	3.7	258
14	Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Modern Pathology, 2010, 23, 781-789.	5.5	236
15	Histologic Subtypes of Ovarian Carcinoma. International Journal of Gynecological Pathology, 2008, PAP, 161-74.	1.4	230
16	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. International Journal of Gynecological Pathology, 2019, 38, S123-S131.	1.4	226
17	Pathologic Ultrastaging Improves Micrometastasis Detection in Sentinel Lymph Nodes During Endometrial Cancer Staging. International Journal of Gynecological Cancer, 2013, 23, 964-970.	2.5	223
18	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. American Journal of Surgical Pathology, 2018, 42, 561-568.	3.7	214

#	Article	IF	Citations
19	Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecologic Oncology, 2003, 90, 378-381.	1.4	211
20	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2009, 33, 14-21.	3.7	211
21	Unusual Endocervical Adenocarcinomas. American Journal of Surgical Pathology, 2011, 35, 633-646.	3.7	208
22	Clinicopathological and molecular characterisation of â€˜multipleâ€classifierâ€™ endometrial carcinomas. Journal of Pathology, 2020, 250, 312-322.	4.5	205
23	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathology, 2010, 23, 1104-1112.	5.5	204
24	Sentinel lymph node mapping for grade 1 endometrial cancer: Is it the answer to the surgical staging dilemma?. Gynecologic Oncology, 2009, 113, 163-169.	1.4	202
25	Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Modern Pathology, 2012, 25, 625-636.	5.5	202
26	Adjuvant gemcitabine plus docetaxel for completely resected stages Iâ€“IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecologic Oncology, 2009, 112, 563-567.	1.4	201
27	Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations. Journal of Clinical Oncology, 2003, 21, 4222-4227.	1.6	199
28	Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Modern Pathology, 2006, 19, 1091-1100.	5.5	199
29	Gastric-type Endocervical Adenocarcinoma. American Journal of Surgical Pathology, 2015, 39, 1449-1457.	3.7	194
30	Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 2019, 38, S64-S74.	1.4	192
31	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434.	7.1	189
32	Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecologic Oncology, 2013, 129, 277-284.	1.4	185
33	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. American Journal of Surgical Pathology, 2018, 42, 791-798.	3.7	182
34	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Modern Pathology, 2015, 28, 505-514.	5.5	180
35	Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities. American Journal of Surgical Pathology, 2009, 33, 925-933.	3.7	178
36	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nature Communications, 2017, 8, 990.	12.8	169

#	Article	IF	Citations
37	The genetic landscape of endometrial clear cell carcinomas. Journal of Pathology, 2017, 243, 230-241.	4.5	168
38	The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecologic Oncology, 2009, 115, 236-238.	1.4	164
39	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute, 2015, 108, djv427.	6.3	164
40	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. International Journal of Gynecological Pathology, 2019, 38, S40-S63.	1.4	164
41	Prognostic Features of Surgical Stage I Uterine Carcinosarcoma. American Journal of Surgical Pathology, 2007, 31, 1653-1661.	3.7	161
42	Squamous cell carcinoma arising in mature cystic teratoma of the ovary: A case series and review of the literature. Gynecologic Oncology, 2007, 105, 321-324.	1.4	158
43	Clinicopathologic Analysis of 187 High-grade Endometrial Carcinomas of Different Histologic Subtypes: Similar Outcomes Belie Distinctive Biologic Differences. American Journal of Surgical Pathology, 2007, 31, 979-987.	3.7	156
44	Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. American Journal of Surgical Pathology, 2009, 33, 1639-1645.	3.7	155
45	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecologic Oncology, 2016, 143, 46-53.	1.4	153
46	Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer, 2004, 101, 1455-1462.	4.1	152
47	Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma. Journal of Clinical Oncology, 2006, 24, 1745-1753.	1.6	152
48	Interobserver and Intraobserver Variability of a Two-tier System for Grading Ovarian Serous Carcinoma. American Journal of Surgical Pathology, 2007, 31, 1168-1174.	3.7	152
49	Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features. American Journal of Surgical Pathology, 2011, 35, 1766-1775.	3.7	151
50	Adjuvant therapy for highâ€grade, uterusâ€limited leiomyosarcoma. Cancer, 2013, 119, 1555-1561.	4.1	150
51	h-Caldesmon, a Novel Smooth Muscle-Specific Antibody, Distinguishes Between Cellular Leiomyoma and Endometrial Stromal Sarcoma. American Journal of Surgical Pathology, 2001, 25, 253-258.	3.7	146
52	Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology, 2016, 48, 291-302.	0.6	146
53	Expression of WT1, CA 125, and GCDFP-15 as Useful Markers in the Differential Diagnosis of Primary Ovarian Carcinomas Versus Metastatic Breast Cancer to the Ovary. American Journal of Surgical Pathology, 2005, 29, 1482-1489.	3.7	145
54	Endometrial Stromal Sarcomas With Unusual Histologic Features. American Journal of Surgical Pathology, 2002, 26, 1142-1150.	3.7	143

#	Article	IF	Citations
55	Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Human Pathology, 2008, 39, 116-125.	2.0	143
56	Serous Endometrial Cancers That Mimic Endometrioid Adenocarcinomas. American Journal of Surgical Pathology, 2004, 28, 1568-1578.	3.7	140
57	TFE3 Translocationâ€“associated Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract. American Journal of Surgical Pathology, 2015, 39, 394-404.	3.7	140
58	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. International Journal of Gynecological Pathology, 2016, 35, 48-55.	1.4	136
59	Unraveling tumorâ€“immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	21.4	136
60	Ovarian Mature Teratomas With Mucinous Epithelial Neoplasms: Morphologic Heterogeneity and Association With Pseudomyxoma Peritonei. American Journal of Surgical Pathology, 2008, 32, 645-655.	3.7	134
61	The outcomes of patients with positive margins after excision for intraepithelial Paget's disease of the vulva. Gynecologic Oncology, 2007, 104, 547-550.	1.4	132
62	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Modern Pathology, 2018, 31, 674-684.	5.5	130
63	Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary. American Journal of Surgical Pathology, 2011, 35, 36-44.	3.7	129
64	Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis. European Radiology, 2017, 27, 2903-2915.	4.5	128
65	A nomogram to predict postresection 5â€year overall survival for patients with uterine leiomyosarcoma. Cancer, 2012, 118, 660-669.	4.1	126
66	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathology, 2009, 22, 469-475.	5.5	125
67	Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 243-253.	1.4	125
68	Endometrial Intraepithelial Carcinoma With Associated Peritoneal Carcinomatosis. American Journal of Surgical Pathology, 2000, 24, 726-732.	3.7	124
69	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Modern Pathology, 2016, 29, 302-314.	5.5	123
70	Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma. American Journal of Surgical Pathology, 2007, 31, 744-751.	3.7	121
71	Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 2009, 113, 105-108.	1.4	121
72	Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. Journal of Clinical Oncology, 2009, 27, 2066-2072.	1.6	119

#	Article	IF	Citations
73	Î²-Catenin and E-Cadherin Expression Patterns in High-Grade Endometrial Carcinoma Are Associated with Histological Subtype. Modern Pathology, 2002, 15, 1032-1037.	5.5	117
74	Molecular Detection of JAZF1-JJAZ1 Gene Fusion in Endometrial Stromal Neoplasms with Classic and Variant Histology. American Journal of Surgical Pathology, 2004, 28, 224-232.	3.7	117
75	Clinicopathologic Features of Rhabdomyosarcoma of Gynecologic Origin in Adults. American Journal of Surgical Pathology, 2007, 31, 382-389.	3.7	117
76	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. American Journal of Surgical Pathology, 2013, 37, 1421-1432.	3.7	115
77	Novel High-grade Endometrial Stromal Sarcoma. American Journal of Surgical Pathology, 2017, 41, 12-24.	3.7	115
78	Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma. Annals of Surgical Oncology, 2016, 23, 1653-1659.	1.5	114
79	Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecologic Oncology, 2008, 110, 408-417.	1.4	113
80	Mullerian Adenosarcomas: An Immunophenotypic Analysis of 35 Cases. American Journal of Surgical Pathology, 2008, 32, 1013-1021.	3.7	113
81	BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. Modern Pathology, 2017, 30, 1251-1261.	5.5	112
82	Microsomal Prostaglandin E Synthase-1 Is Overexpressed in Inflammatory Bowel Disease. Journal of Biological Chemistry, 2004, 279, 12647-12658.	3.4	111
83	Endometrial Carcinomas in Women Aged 40 Years and Younger: Tumors Associated With Loss of DNA Mismatch Repair Proteins Comprise a Distinct Clinicopathologic Subset. American Journal of Surgical Pathology, 2009, 33, 1869-1877.	3.7	110
84	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecologic Oncology, 2018, 150, 274-281.	1.4	105
85	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. Modern Pathology, 2015, 28, 1603-1612.	5.5	100
86	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	7.0	100
87	Transitional Cell Neoplasms of the Ovary and Urinary Bladder: A Comparative Immunohistochemical Analysis. International Journal of Gynecological Pathology, 1996, 15, 257-265.	1.4	99
88	High Frequency of JAZF1-JJAZ1 Gene Fusion in Endometrial Stromal Tumors With Smooth Muscle Differentiation by Interphase FISH Detection. American Journal of Surgical Pathology, 2007, 31, 1277-1284.	3.7	95
89	Clinical Outcome of Isolated Serous Tubal Intraepithelial Carcinomas (STIC). International Journal of Gynecological Cancer, 2013, 23, 1603-1611.	2.5	95
90	Uterine adenosarcomas are mesenchymal neoplasms. Journal of Pathology, 2016, 238, 381-388.	4.5	94

#	Article	IF	Citations
91	Unusual DNA mismatch repairâ€“deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Human Pathology, 2012, 43, 1677-1687.	2.0	93
92	Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic Oncology, 2010, 116, 424-429.	1.4	92
93	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. European Radiology, 2017, 27, 3991-4001.	4.5	92
94	Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma. PLoS ONE, 2010, 5, e10358.	2.5	90
95	High grade undifferentiated uterine sarcoma: Surgery, treatment, and survival outcomes. Gynecologic Oncology, 2012, 127, 27-31.	1.4	89
96	TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. International Journal of Gynecological Pathology, 2016, 35, 289-300.	1.4	89
97	Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecologic Oncology, 2006, 103, 31-34.	1.4	87
98	p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Modern Pathology, 2010, 23, 80-92.	5.5	87
99	Endometrial carcinomas with ambiguous features. Seminars in Diagnostic Pathology, 2010, 27, 261-273.	1.5	87
100	Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecologic Oncology, 2013, 130, 452-456.	1.4	87
101	Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type. American Journal of Surgical Pathology, 2016, 40, 395-403.	3.7	87
102	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Modern Pathology, 2016, 29, 1586-1593.	5.5	87
103	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2016, 23, 196-202.	1.5	86
104	Difficulties in Assessing the Depth of Myometrial Invasion in Endometrial Carcinoma. International Journal of Gynecological Pathology, 2007, 26, 115-123.	1.4	85
105	Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. Modern Pathology, 2014, 27, 1020-1027.	5.5	85
106	Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma. American Journal of Surgical Pathology, 2008, 32, 955-964.	3.7	84
107	Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). American Journal of Surgical Pathology, 2019, 43, 466-474.	3.7	84
108	Diagnostic Accuracy of Cervical Low-Grade Squamous Intraepithelial Lesions Is Improved With MIB-1 Immunostaining. American Journal of Surgical Pathology, 2002, 26, 70-75.	3.7	83

#	Article	IF	Citations
109	Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecologic Oncology, 2013, 129, 140-144.	1.4	83
110	Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?. American Journal of Obstetrics and Gynecology, 2008, 198, 457.e1-457.e6.	1.3	82
111	Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCT) Lack the JAZF1-JJAZ1 Translocation Frequently Seen in Endometrial Stromal Tumors. American Journal of Surgical Pathology, 2009, 33, 1206-1212.	3.7	82
112	Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecologic Oncology, 2017, 147, 541-548.	1.4	82
113	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. American Journal of Surgical Pathology, 2017, 41, 245-252.	3.7	81
114	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Modern Pathology, 2016, 29, 1390-1398.	5.5	80
115	Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas. American Journal of Surgical Pathology, 2018, 42, 989-1000.	3.7	80
116	Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions. Gynecologic Oncology, 2014, 134, 410-418.	1.4	79
117	Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins. American Journal of Surgical Pathology, 2018, 42, 76-83.	3.7	78
118	Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma. American Journal of Surgical Pathology, 2004, 28, 147-159.	3.7	77
119	Distinction of endometrial stromal sarcomas from â€˜hemangiopericytomatousâ€™ tumors using a panel of immunohistochemical stains. Modern Pathology, 2005, 18, 40-47.	5.5	77
120	Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecologic Oncology, 2004, 93, 301-306.	1.4	76
121	Patterns of p53 immunoreactivity in endometrial carcinomas: â€˜all or nothingâ€™ staining is of importance. Histopathology, 2011, 59, 786-788.	2.9	76
122	Sentinel lymph node mapping with pathologic ultrastaging: A valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecologic Oncology, 2013, 131, 714-719.	1.4	76
123	Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus. American Journal of Surgical Pathology, 2011, 35, 522-529.	3.7	75
124	Perivascular epithelioid tumours (PEComas) of the gynaecological tract. Journal of Clinical Pathology, 2015, 68, 418-426.	2.0	75
125	Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 201-209.	4.9	75
126	A Comparative Analysis of 57 Serous Borderline Tumors With and Without a Noninvasive Micropapillary Component. American Journal of Surgical Pathology, 2002, 26, 592-600.	3.7	73

#	Article	IF	Citations
127	Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecologic Oncology, 2012, 124, 558-562.	1.4	73
128	Pathologic Scoring of PTEN Immunohistochemistry in Endometrial Carcinoma is Highly Reproducible. International Journal of Gynecological Pathology, 2012, 31, 48-56.	1.4	72
129	Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecologic Oncology, 2004, 94, 449-455.	1.4	71
130	Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Modern Pathology, 2014, 27, 751-757.	5.5	71
131	Phytoestrogen consumption and endometrial cancer risk: a population-based caseâ€“control study in New Jersey. Cancer Causes and Control, 2009, 20, 1117-1127.	1.8	70
132	The Impact of Race and Comorbidity on Survival in Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 753-760.	2.5	70
133	Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 2008, 111, 244-248.	1.4	69
134	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. Annals of Surgical Oncology, 2016, 23, 2522-2528.	1.5	69
135	ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Modern Pathology, 2013, 26, 1514-1524.	5.5	68
136	International Endocervical Adenocarcinoma Criteria and Classification. American Journal of Surgical Pathology, 2019, 43, 75-83.	3.7	66
137	Endometrial Carcinoma in Women Aged 40 Years and Younger. Archives of Pathology and Laboratory Medicine, 2014, 138, 335-342.	2.5	65
138	Histopathological features of endometrial carcinomas associated with <scp>POLE</scp> mutations: implications for decisions about adjuvant therapy. Histopathology, 2016, 68, 916-924.	2.9	65
139	Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Modern Pathology, 2005, 18, 903-911.	5.5	64
140	Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. Gynecologic Oncology, 2018, 151, 235-242.	1.4	63
141	Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. Modern Pathology, 2016, 29, 60-66.	5.5	62
142	Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. American Journal of Surgical Pathology, 2016, 40, 302-312.	3.7	61
143	Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas. American Journal of Surgical Pathology, 2019, 43, 662-669.	3.7	61
144	The Revised 2009 FIGO Staging System for Endometrial Cancer: Should the 1988 FIGO Stages IA and IB Be Altered?. International Journal of Gynecological Cancer, 2011, 21, 511-516.	2.5	60

#	Article	IF	Citations
145	Interobserver Variability in the Interpretation of Tumor Cell Necrosis in Uterine Leiomyosarcoma. American Journal of Surgical Pathology, 2013, 37, 650-658.	3.7	60
146	Distinctive p53 and mdm2 Immunohistochemical Expression Profiles Suggest Different Pathogenetic Pathways in Poorly Differentiated Endometrial Carcinoma. International Journal of Gynecological Pathology, 1998, 17, 129-134.	1.4	59
147	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	7.0	59
148	Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecologic Oncology, 2012, 125, 409-413.	1.4	58
149	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Modern Pathology, 2020, 33, 871-879.	5.5	58
150	Radiation-associated endometrial cancers are prognostically unfavorable tumors: A clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecologic Oncology, 2006, 103, 948-951.	1.4	57
151	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. Gynecologic Oncology, 2016, 142, 139-143.	1.4	57
152	MECHANISM OF HEALING FOLLOWING THE SNODGRASS REPAIR. Journal of Urology, 2001, 165, 277-279.	0.4	55
153	Recent advances in invasive adenocarcinoma of the cervix. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 537-549.	2.8	55
154	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight, 2017, 2, e89760.	5.0	55
155	Ependymomas of the Central Nervous System and Adult Extra-axial Ependymomas are Morphologically and Immunohistochemically Distinctâ€"A Comparative Study With Assessment of Ovarian Carcinomas for Expression of Glial Fibrillary Acidic Protein. American Journal of Surgical Pathology, 2008, 32, 710-718.	3.7	54
156	â€œLow-Grade Leiomyosarcomaâ€•and Late-Recurring Smooth Muscle Tumors of the Uterus. American Journal of Surgical Pathology, 2011, 35, 1626-1637.	3.7	54
157	Highâ€grade endometrial carcinomas â€“ strategies for typing. Histopathology, 2013, 62, 89-110.	2.9	54
158	BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas. American Journal of Surgical Pathology, 2013, 37, 138-146.	3.7	54
159	Immunophenotypic features of dedifferentiated endometrial carcinoma â€“ insights from <scp>BRG</scp>1/<scp>INI</scp>1â€deficient tumours. Histopathology, 2016, 69, 560-569.	2.9	54
160	Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors. American Journal of Surgical Pathology, 2019, 43, 382-388.	3.7	53
161	Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecologic Oncology, 2011, 121, 319-322.	1.4	52
162	Morphologic Features of Uterine Leiomyomas Associated With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. American Journal of Surgical Pathology, 2011, 35, 1235-1237.	3.7	51

#	Article	IF	Citations
163	Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. Modern Pathology, 2017, 30, 1476-1488.	5.5	51
164	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
165	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. American Journal of Surgical Pathology, 2016, 40, 166-180.	3.7	51
166	Lysophosphatidic Acid Acyltransferase-Î² Is a Prognostic Marker and Therapeutic Target in Gynecologic Malignancies. Cancer Research, 2005, 65, 9415-9425.	0.9	50
167	Ovarian Clear Cell Carcinoma With Papillary Features: A Potential Mimic of Serous Tumor of Low Malignant Potential. American Journal of Surgical Pathology, 2008, 32, 269-274.	3.7	50
168	Association between Morphologic CT Imaging Traits and Prognostically Relevant Gene Signatures in Women with High-Grade Serous Ovarian Cancer: A Hypothesis-generating Study. Radiology, 2015, 274, 742-751.	7.3	50
169	Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. Abdominal Radiology, 2019, 44, 2040-2047.	2.1	50
170	Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecologic Oncology, 2006, 101, 86-91.	1.4	49
171	Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas. Clinical Cancer Research, 2021, 27, 2613-2623.	7.0	49
172	Atypical Polypoid Adenomyofibroma (APA) Versus Well-Differentiated Endometrial Carcinoma With Prominent Stromal Matrix: An Immunohistochemical Study. International Journal of Gynecological Pathology, 1996, 15, 209-216.	1.4	48
173	The Diagnostic and Biological Implications of Laminin Expression in Serous Tubal Intraepithelial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1826-1834.	3.7	48
174	Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clinical Cancer Research, 2003, 9, 3425-30.	7.0	48
175	Histologically Bland â€œExtremely Well Differentiatedâ€•Thyroid Carcinomas Arising in Struma Ovarii can Recur and Metastasize. International Journal of Gynecological Pathology, 2009, 28, 222-230.	1.4	47
176	Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. American Journal of Obstetrics and Gynecology, 2010, 203, 349.e1-349.e6.	1.3	47
177	Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2017, 24, 1965-1971.	1.5	47
178	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. Cancer Prevention Research, 2018, 11, 697-706.	1.5	47
179	Perihepatic Metastases from Ovarian Cancer: Sensitivity and Specificity of CT for the Detection of Metastases with and Those without Liver Parenchymal Invasion. Radiology, 2008, 248, 511-517.	7.3	46
180	Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology, 2014, 64, 284-292.	2.9	46

#	Article	IF	Citations
181	High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology, 2017, 285, 472-481.	7.3	46
182	Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma. Archives of Pathology and Laboratory Medicine, 2016, 140, 836-843.	2.5	45
183	Molecular insights into the classification of high-grade endometrial carcinoma. Pathology, 2018, 50, 151-161.	0.6	45
184	Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer, 2006, 107, 90-98.	4.1	44
185	Endometrial Carcinomas With Clear Cells. International Journal of Gynecological Pathology, 2015, 34, 323-333.	1.4	44
186	Mesenchymal Tumors of the Uterus. , 2011, , 453-527.		44
187	Cyclin D1 Expression in High-Grade Endometrial Carcinomas???Association with Histologic Subtype. International Journal of Gynecological Pathology, 2000, 19, 329-334.	1.4	43
188	Significant Variation in the Assessment of Cervical Involvement in Endometrial Carcinoma. American Journal of Surgical Pathology, 2011, 35, 289-294.	3.7	43
189	Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 462-472.	1.2	43
190	Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. Modern Pathology, 2014, 27, 1405-1411.	5.5	42
191	A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer. International Journal of Gynecological Cancer, 2017, 27, 743-747.	2.5	42
192	Strategies for Distinguishing Low-grade Endometrioid and Serous Carcinomas of Endometrium. Advances in Anatomic Pathology, 2012, 19, 1-10.	4.3	41
193	Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Human Pathology, 2014, 45, 2430-2436.	2.0	41
194	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecologic Oncology, 2018, 150, 127-135.	1.4	41
195	Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 2021, 40, S75-S91.	1.4	41
196	Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. Gynecologic Oncology, 2010, 117, 229-233.	1.4	40
197	Histological features associated with occult lymph node metastasis in <scp>FIGO</scp> clinical stage <scp>I</scp>, grade <scp>I</scp> endometrioid carcinoma. Histopathology, 2014, 64, 389-398.	2.9	40
198	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. International Journal of Gynecological Pathology, 2017, 36, 555-561.	1.4	40

#	Article	IF	Citations
199	The Value of MR Imaging When the Site of Uterine Cancer Origin Is Uncertain. Radiology, 2011, 258, 785-792.	7.3	39
200	Annexinâ€A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer, 2015, 136, 1863-1873.	5.1	39
201	Lysophosphatidic acid acyltransferase-Î² (LPAAT-Î²) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. Cancer, 2006, 107, 1511-1519.	4.1	38
202	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. Modern Pathology, 2020, 33, 1606-1617.	5.5	38
203	<scp>SWI</scp>/<scp>SNF</scp>â€deficiency defines highly aggressive undifferentiated endometrial carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 144-153.	3.0	38
204	The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. International Journal of Gynecological Pathology, 2016, 35, 16-24.	1.4	37
205	Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. Gynecologic Oncology, 2020, 156, 70-76.	1.4	37
206	Extrauterine Epithelioid Trophoblastic Tumors Presenting as Primary Lung Carcinomas. American Journal of Surgical Pathology, 2009, 33, 1809-1814.	3.7	36
207	Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 902-915.	4.1	36
208	Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage Iâ€“II serous endometrial cancer. Gynecologic Oncology, 2009, 112, 142-145.	1.4	35
209	Peritoneal inclusion cysts: clinical characteristics and imaging features. European Radiology, 2013, 23, 1167-1174.	4.5	35
210	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic Oncology, 2020, 156, 194-202.	1.4	35
211	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Scientific Reports, 2020, 10, 17769.	3.3	35
212	Patterns of recurrence and role of adjuvant chemotherapy in stage IIâ€“IV serous ovarian borderline tumors. Gynecologic Oncology, 2010, 119, 270-273.	1.4	34
213	Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nature Communications, 2020, 11, 44.	12.8	34
214	Endometrial Carcinomas with a â€œSerousâ€•Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations. American Journal of Surgical Pathology, 2020, 44, 641-648.	3.7	34
215	Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecologic Oncology, 2006, 101, 322-326.	1.4	33
216	Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: Pathologic pitfalls and the application of an objective scoring system. Gynecologic Oncology, 2008, 110, 316-323.	1.4	33

#	Article	IF	Citations
217	Urothelial Carcinoma Involving the Gynecologic Tract. American Journal of Surgical Pathology, 2012, 36, 1058-1065.	3.7	33
218	Genomic landscape of endometrial carcinomas of no specific molecular profile. Modern Pathology, 2022, 35, 1269-1278.	5.5	33
219	Absence of Y chromosome in human placental site trophoblastic tumor. Modern Pathology, 2007, 20, 1055-1060.	5.5	32
220	Low-grade Serous Neoplasms of the Ovary With Transformation to High-grade Carcinomas. International Journal of Gynecological Pathology, 2012, 31, 423-428.	1.4	32
221	HNF-1Î² in Ovarian Carcinomas With Serous and Clear Cell Change. International Journal of Gynecological Pathology, 2013, 32, 541-546.	1.4	32
222	Grading Uterine Endometrioid Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1583-1587.	3.7	32
223	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. Journal of the National Cancer Institute, 2015, 107, .	6.3	32
224	CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas. American Journal of Roentgenology, 2018, 210, 918-926.	2.2	32
225	Micropapillary Cervical Adenocarcinoma. American Journal of Surgical Pathology, 2019, 43, 802-809.	3.7	32
226	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. American Journal of Surgical Pathology, 2021, 45, 77-92.	3.7	30
227	Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstetrics and Gynecology, 2003, 101, 941-945.	2.4	29
228	Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes and Control, 2008, 19, 955-963.	1.8	29
229	Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer. Clinical Cancer Research, 2010, 16, 3954-3963.	7.0	29
230	Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecologic Oncology, 2012, 126, 224-228.	1.4	29
231	Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. Cancer Research, 2020, 80, 3466-3479.	0.9	29
232	Gastrointestinal adenocarcinoma arising in a mature cystic teratoma of the ovary. Gynecologic Oncology, 2004, 94, 597-599.	1.4	28
233	Expression of cancerâ€“testis antigens in endometrial carcinomas using a tissue microarray. Modern Pathology, 2005, 18, 119-126.	5.5	28
234	PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. American Journal of Surgical Pathology, 2019, 43, 810-818.	3.7	28

#	Article	IF	Citations
235	Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecologic Oncology, 2004, 95, 570-575.	1.4	27
236	Recommendations for the reporting of fallopian tube neoplasms. Human Pathology, 2007, 38, 1160.e1-1160.e7.	2.0	27
237	Epithelial membrane proteinâ€2 expression is an early predictor of endometrial cancer development. Cancer, 2010, 116, 4718-4726.	4.1	27
238	Updates in diagnostic immunohistochemistry in endometrial carcinoma. Seminars in Diagnostic Pathology, 2014, 31, 205-215.	1.5	27
239	Tumoral Displacement into Fallopian Tubes in Patients Undergoing Robotically Assisted Hysterectomy for Newly Diagnosed Endometrial Cancer. International Journal of Gynecological Pathology, 2013, 32, 188-192.	1.4	26
240	Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes. American Journal of Surgical Pathology, 2016, 40, 404-409.	3.7	26
241	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. Modern Pathology, 2020, 33, 1861-1870.	5.5	26
242	Redefining Stage I Endometrial Cancer: Incorporating Histology, a Binary Grading System, Myometrial Invasion, and Lymph Node Assessment. International Journal of Gynecological Cancer, 2013, 23, 1620-1628.	2.5	25
243	Frequent loss of claudinâ€4 expression in dedifferentiated and undifferentiated endometrial carcinomas. Histopathology, 2018, 73, 299-305.	2.9	25
244	The roles of pathology in targeted therapy of women with gynecologic cancers. Gynecologic Oncology, 2018, 148, 213-221.	1.4	24
245	Serous Adenocarcinoma of the Inguinal Region Arising from Endometriosis followed by a Successful Pregnancy. Gynecologic Oncology, 2002, 87, 152-154.	1.4	23
246	Problems with the current diagnostic approach to complex atypical endometrial hyperplasia. Cancer, 2006, 106, 729-731.	4.1	23
247	Histologic Evaluation of Prophylactic Hysterectomy and Oophorectomy in Lynch Syndrome. American Journal of Surgical Pathology, 2013, 37, 579-585.	3.7	23
248	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. Modern Pathology, 2015, 28, 1492-1503.	5.5	23
249	p16 Expression in Squamous and Trophoblastic Lesions of the Upper Female Genital Tract. International Journal of Gynecological Pathology, 2010, 29, 513-522.	1.4	22
250	Clinicopathologic Analysis of Matched Primary and Recurrent Endometrial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1771-1781.	3.7	22
251	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Modern Pathology, 2013, 26, 1197-1203.	5.5	22
252	DNA Mismatch Repairâ€“deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas. American Journal of Surgical Pathology, 2020, 44, 1573-1579.	3.7	22

#	Article	IF	Citations
253	Morphologic Changes in Ovarian Carcinoma After Neoadjuvant Chemotherapy: Report of a Case Showing Extensive Clear Cell Changes Mimicking Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2009, 28, 442-446.	1.4	21
254	Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. Gynecologic Oncology, 2013, 128, 83-87.	1.4	21
255	Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome. Modern Pathology, 2016, 29, S59-S77.	5.5	21
256	BCOR Expression in Mullerian Adenosarcoma. American Journal of Surgical Pathology, 2020, 44, 765-770.	3.7	21
257	Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Cervix. American Journal of Surgical Pathology, 2020, 44, 873-880.	3.7	21
258	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
259	Endometrial Giant Cell Carcinoma: A Case Series and Review of the Spectrum of Endometrial Neoplasms Containing Giant Cells. American Journal of Surgical Pathology, 2010, 34, 1132-1138.	3.7	20
260	Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. International Journal of Gynecological Cancer, 2016, 26, 120-124.	2.5	20
261	Clinical patterns and genomic profiling of recurrent â€˜ultra-low riskâ€™ endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 717-723.	2.5	20
262	Characterization of Adnexal Masses Using Feature Analysis at Contrast-Enhanced Helical Computed Tomography. Journal of Computer Assisted Tomography, 2008, 32, 533-540.	0.9	19
263	Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. JCO Precision Oncology, 2019, 3, 1-11.	3.0	19
264	TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2022, 40, 3289-3300.	1.6	19
265	Immunoreactivity of p16 in anal cytology specimens. Cancer, 2006, 108, 66-71.	4.1	18
266	Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. International Journal of Gynecological Pathology, 2019, 38, 263-275.	1.4	18
267	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology, 2019, 152, 38-45.	1.4	18
268	Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Modern Pathology, 2021, 34, 490-501.	5.5	18
269	Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum). Histopathology, 2012, 61, 329-339.	2.9	17
270	The Impact on Survival of an Extensive Sex Cord-like Component in Mullerian Adenosarcomas. International Journal of Gynecological Pathology, 2016, 35, 147-152.	1.4	17

#	Article	IF	Citations
271	Mucinous ovarian carcinoma: Slippery business. Cancer, 2011, 117, 451-453.	4.1	16
272	Abdominal wall endometriosis: differentiation from other masses using CT features. Abdominal Radiology, 2017, 42, 1517-1523.	2.1	16
273	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 535-544.	1.4	16
274	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 2022, 35, 117-127.	5.5	16
275	Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma. Modern Pathology, 2022, 35, 274-282.	5.5	16
276	Laser-assisted demucosalized gastrocystoplasty with autoaugmentation in a canine model. Urology, 2000, 55, 437-442.	1.0	15
277	EVALUATION OF OCTYLCYANOACRYLATE FOR WOUND REPAIR OF CLINICAL CIRCUMCISION AND HUMAN SKIN INCISIONAL HEALING IN A NUDE RAT MODEL. Journal of Urology, 2002, 167, 677-679.	0.4	15
278	PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. Gynecologic Oncology, 2015, 137, 321-328.	1.4	15
279	Invasive Stratified Mucinous Carcinoma (iSMC) of the Cervix Often Presents With High-risk Features That Are Determinants of Poor Outcome. American Journal of Surgical Pathology, 2020, 44, 1374-1380.	3.7	15
280	International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings. International Journal of Gynecological Pathology, 2021, 40, 533-540.	1.4	15
281	Clinicopathologic Analysis of Low-stage Sporadic Ovarian Carcinomas. American Journal of Surgical Pathology, 2013, 37, 356-367.	3.7	14
282	Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment. Gynecologic Oncology, 2018, 151, 395-400.	1.4	14
283	Trefoil Factor 2 (TFF2) as a Surrogate Marker for Endocervical Gastric-type Carcinoma. International Journal of Gynecological Pathology, 2021, 40, 65-72.	1.4	14
284	Endometrial Carcinoma. , 2011, , 394-452.		13
285	Tumor Suppressor Gene, Cell Surface Adhesion Molecule, and Multidrug Resistance in MÃ¼llerian Serous Carcinomas: Clinical Divergence without Immunophenotypic Differences. Gynecologic Oncology, 2000, 79, 430-437.	1.4	12
286	Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology. American Journal of Obstetrics and Gynecology, 2010, 202, 278.e1-278.e6.	1.3	12
287	Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases. International Journal of Gynecological Pathology, 2020, 39, 72-78.	1.4	12
288	GTF2A1-NCOA2-Associated Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Shows Focal Rhabdoid Morphology and Aggressive Behavior. American Journal of Surgical Pathology, 2021, 45, 1725-1728.	3.7	12

#	Article	IF	Citations
289	Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated With Poor Outcome. American Journal of Surgical Pathology, 2022, 46, 765-773.	3.7	12
290	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. Molecular Oncology, 2017, 11, 913-926.	4.6	11
291	Somatic genetic alterations in synchronous and metachronous lowâ€grade serous tumours and highâ€grade carcinomas of the adnexa. Histopathology, 2019, 74, 638-650.	2.9	11
292	Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization. Journal of Pathology and Translational Medicine, 2020, 54, 480-488.	1.1	11
293	Full-Thickness Human Foreskin Transplantation onto Nude Rats as an In Vivo Model of Acute Human Wound Healing. Plastic and Reconstructive Surgery, 2003, 111, 1988-1997.	1.4	10
294	Uterine mesenchymal tumors: a review of selected topics. Diagnostic Histopathology, 2008, 14, 175-188.	0.4	10
295	Endometrial Carcinoma. , 2019, , 473-533.		10
296	Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles. International Journal of Gynecological Pathology, 2019, 38, 552-561.	1.4	10
297	Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. JCO Precision Oncology, 2019, 3, 1-9.	3.0	10
298	The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. Gynecologic Oncology, 2006, 102, 315-318.	1.4	9
299	Immunohistology of the Female Genital Tract. , 2010, , 690-762.		9
300	The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. Gynecologic Oncology, 2021, 160, 660-668.	1.4	9
301	Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma. Gynecologic Oncology, 2022, 165, 287-292.	1.4	9
302	Claudin-18 as a Promising Surrogate Marker for Endocervical Gastric-type Carcinoma. American Journal of Surgical Pathology, 2022, 46, 628-636.	3.7	9
303	Nonserous Ovarian Epithelial Tumors. Surgical Pathology Clinics, 2011, 4, 397-459.	1.7	8
304	Ovarian Hemangiomas Do Not Harbor EWSR1 Rearrangements. International Journal of Gynecological Pathology, 2015, 34, 437-444.	1.4	7
305	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	2.4	7
306	Clinically inapparent invasive vulvar carcinoma in an area of persistent Pagetâ€™s disease: a case report. Gynecologic Oncology, 2003, 88, 440-443.	1.4	6

#	Article	IF	Citations
307	High-Grade Endometrial Carcinomas. Surgical Pathology Clinics, 2011, 4, 199-241.	1.7	6
308	Letter to the editor regarding â€˜Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expressionâ€˜. Modern Pathology, 2011, 24, 1281-1282.	5.5	6
309	Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma. International Journal of Gynecological Pathology, 2014, 33, 282-287.	1.4	6
310	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. International Journal of Gynecological Cancer, 2020, 30, 1162-1168.	2.5	6
311	Effect of laser welding with human serum albumin on the expression of P-selectin on platelets. , 1999, 25, 438-444.		5
312	Recommendations for the reporting of fallopian tube neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 25-29.	2.8	5
313	Mixed MÃ¼llerian Tumors of the Female Genital Tract. Surgical Pathology Clinics, 2009, 2, 707-730.	1.7	5
314	Typing of ovarian carcinomas: an update. Diagnostic Histopathology, 2011, 17, 165-177.	0.4	5
315	Low-Stage High-Grade Serous Ovarian Carcinomas. International Journal of Gynecological Pathology, 2016, 35, 222-229.	1.4	5
316	Diagnostic Performance of Computed Tomography for Preoperative Staging of Patients with Non-endometrioid Carcinomas of the Uterine Corpus. Annals of Surgical Oncology, 2016, 23, 1271-1278.	1.5	5
317	ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. Modern Pathology, 2021, , .	5.5	5
318	Clinical correlation of lymphovascular invasion and Silva pattern of invasion in early-stage endocervical adenocarcinoma: proposed binary Silva classification system. Pathology, 2022, 54, 548-554.	0.6	5
319	Preoperative CT-based nomogram for predicting overall survival in women with non-endometrioid carcinomas of the uterine corpus. Abdominal Imaging, 2015, 40, 1761-1768.	2.0	4
320	Proteomic analysis of transitional cell carcinomaâ€“like variant of tubo-ovarian high-grade serous carcinoma. Human Pathology, 2020, 101, 40-52.	2.0	4
321	Immunohistology of the Female Genital Tract. , 2006, , 637-698.		4
322	Horizontal tumor extent (HZTE) has limited prognostic significance in 2018 FIGO stage I endocervical adenocarcinoma (ECA): a retrospective study of 416 cases. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	2.5	4
323	Mesenchymal Tumors of the Uterus. , 2019, , 535-647.		3
324	Cytologic features of undifferentiated and dedifferentiated carcinomas of the endometrium. Cancer Cytopathology, 2021, 129, 121-131.	2.4	3

#	Article	IF	Citations
325	Neoplastic Lesions of the Cervix. , 2020, , 227-293.		3
326	Melanocytic marker expression and TSC alterations/TFE3 fusions in uterine PEComas. Modern Pathology, 2022, 35, 449-450.	5.5	3
327	Endometrial Undifferentiated Carcinomas. , 2011, 16, 115-118.		2
328	DNA Repair Mutations and Outcomes in Ovarian Cancerâ€"Letter. Clinical Cancer Research, 2015, 21, 658-658.	7.0	2
329	Gynecologic Manifestations of Less Commonly Encountered Hereditary Syndromes. Surgical Pathology Clinics, 2016, 9, 269-287.	1.7	2
330	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. Histopathology, 2017, 71, 480-487.	2.9	2
331	Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas. International Journal of Gynecological Pathology, 2017, 36, 386-392.	1.4	2
332	A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract. Seminars in Diagnostic Pathology, 2018, 35, 95-107.	1.5	2
333	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 680-688.	2.5	2
334	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Gynecologic Oncology, 2021, 161, 521-526.	1.4	2
335	Hand-assisted demucosalized gastrocystoplasty comparing different tissue closure methods. Urology, 2001, 58, 625-630.	1.0	1
336	Corrigendum to â€œUterine mesenchymal tumors: a review of selected topicsâ€•[Diagn Histopathol, 14 (2008) 175â€“188]. Diagnostic Histopathology, 2008, 14, 251.	0.4	1
337	Uterine Cancer. , 2009, , 51-86.		1
338	Reply to Singh et al.. Modern Pathology, 2021, 34, 1033-1034.	5.5	1
339	Survey on Reporting of Endometrial Biopsies From Women on Progestogen Therapy for Endometrial Atypical Hyperplasia/Endometrioid Carcinoma. International Journal of Gynecological Pathology, 2022, 41, 142-150.	1.4	1
340	Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. Journal of the National Cancer Institute, 0, , .	6.3	1
341	Diseases of the Peritoneum. , 2009, , 615-644.		0
342	Familial Tumors of the Uterine Corpus. Surgical Pathology Clinics, 2011, 4, 243-259.	1.7	0

#	Article	IF	Citations
343	Gynecologic Pathologists: Physicians at the Crossroads of Diagnosis and Clinical Care. Surgical Pathology Clinics, 2011, 4, xi-xii.	1.7	0
344	Endometrial carcinoma precursors: hyperplasia and endometrial intraepithelial neoplasia. , 0, , 110-126.		0
345	Endometrial stromal tumors. , 0, , 251-263.		0
346	Letter to the Editor regarding the manuscript entitled: â€œPrevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndromeâ€• by Lachiewicz et al. (Gynecol Oncol. 2014; 132: 434â€“437). Gynecologic Oncology Reports, 2015, 14, 41.	0.6	0
347	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. Obstetrical and Gynecological Survey, 2015, 70, 624-626.	0.4	0
348	Uterine Cancer: Pathology. Current Clinical Oncology, 2015, , 47-81.	0.0	0
349	The 2015 Fred W. Stewart Award: Robert H. Young, MD. American Journal of Surgical Pathology, 2016, 40, 1435-1436.	3.7	0
350	Mesenchymal Tumors of the Uterus. , 2018, , 1-115.		0
351	Endometrial Carcinoma. , 2018, , 1-62.		0
352	A pragmatic approach to carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology Reports, 2019, 27, 74.	0.6	0
353	Frozen Section of Ovarian Lesions. , 2011, , 15-36.		0
354	Pathology of Clear Cell Tumors. , 2011, , 91-104.		0
355	Diseases of the Peritoneum. , 2020, , 829-870.		0
356	Clear cell adenocarcinoma and other uterine corpus carcinomas, including unusual variants. , 0, , 174-195.		0
357	Adenofibroma and adenosarcoma. , 0, , 205-218.		0
358	Other uterine mesenchymal tumors. , 0, , 264-281.		0